Worlds biggest weed dealer ever. Canada’s Aurora Cannabis is king of the crop after making the worlds biggest weed deal ever after purchasing CanniMed. In what was originally an all stock bid, turned into high drama with CanniMed accusing Aurora of a hostile takeover. This deal, worth $CAD1.1 billion ($US852 million), makes Aurora the world’s largest cannabis company in the world. Aurora has knocked Canopy Growth of the top spot down to number 2 in the world. Aurora is worth $CAD7.8 billion compared to the value of Canopy Growth of $CAD6.9 billion. But, Canopy growth still holds top spot for its cannabis production capacity.
Lawsuit filed against AuroraOn January 12, CanniMed announced it filed a lawsuit against Aurora worth $CAD725 million. The lawsuit alleged many wrongdoings by Aurora in its hostile bid to take CanniMed over. The company also sought personal damages from one former and one current board member. They alleging they took part in the purported plot. Aurora’s chief corporate officer, Cam Battley, said CanniMed was suing its own shareholders and that things at CanniMed were a mess. He said the company going public had exposed them to the realities of trading on the open stock market. As the United States continues to face challenged because state and federal governments cannot agree, Canada’s cannabis industry surges ahead. Aurora’s deal with CanniMed makes it the largest weed deal in history.
Aurora’s amended press releaseCanniMed accused Aurora of a hostile takeover and called for government intervention. On December 22, 2017, the Ontario Securities Commission (OSC) and the Financial and Consumer Affairs Authority of Saskatchewan (FCAAS) ordered Aurora to amend its press release. Aurora has amended the background to their offer according to the Order of the Securities Regulators. The amended press release addresses the following:
- How Aurora became aware the CanniMed Board were meeting with Newstrike Resources on November 13, 2017.
- How Aurora obtained any other information, whether directly or indirectly, from anyone in a privileged relationship with CanniMed.
- Whether Aurora had any other information that could affect the decision of CanniMed shareholders to make a decision to accept Aurora’s offer or not.